Why Did GlucoTrack Stock Plunge 18.88% After Surge?

On June 26, 2025, GlucoTrack's stock experienced a significant drop of 18.88% in pre-market trading.

GlucoTrack recently announced positive results from its implantable blood glucose monitor study, which has boosted retail sentiment to a three-month high. The company's continuous blood glucose monitor (CBGM) achieved a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched data points, demonstrating excellent accuracy and a 99% data capture rate with no serious adverse events reported.

The study, conducted at Instituto do Coração in São Paulo, Brazil, enrolled 10 patients with Type 1 or Type 2 diabetes on intensive insulin therapy. The device showed minimal lag versus venous blood glucose and consistent performance during glucose tolerance testing. The fully implantable system includes a sensor lead placed in the subclavian vein and subcutaneous electronics that transmit data to a mobile app, designed for 3-year use without an external wearable.

Following the presentation of these positive results at the American Diabetes Association's 85th Scientific Sessions, GlucoTrack's stock surged 40.26% to $8.24. The company plans to initiate a long-term early feasibility study in the third quarter of 2025 to assess safety and durability over an extended period. The device remains investigational and is not yet approved for commercial use.